- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Identifying and Managing MASH Patients at Risk for Fibrosis
Panelists discuss how noninvasive risk assessments enable early detection and targeted management of fibrosis in MASH patients.
EP: 1.Understanding the Metabolic–Hepatic Connection in MASH
EP: 2.Enhancing Early Detection and Diagnosis in MASH
EP: 3.Recognizing Risk and the Broader Health Impact in MASH
EP: 4.Evidence for GLP-1 Therapy in MASH
EP: 5.Expanding the Therapeutic Horizon in MASH
EP: 6.Balancing Clinical and Economic Considerations in Treatment Adoption
EP: 7.Identifying and Managing MASH Patients at Risk for Fibrosis
EP: 8.Coordinating Care Across the MASH Continuum
Panelists discuss how to identify patients most likely to progress from MASH to fibrosis using noninvasive diagnostic tools. They highlight fibrosis scoring systems, elastography, and biochemical markers as key to stratifying risk without biopsy reliance.
They emphasize that integrating these assessments into obesity and diabetes management allows for timely intervention before irreversible damage occurs. This approach also supports coverage and policy decisions that prioritize preventive care.
Panelists conclude that expanding access to advanced screening technologies within clinical practice and employer wellness programs can meaningfully reduce disease progression rates.
